ValuEngine Downgrades Gilead Sciences (NASDAQ:GILD) to Sell

ValuEngine downgraded shares of Gilead Sciences (NASDAQ:GILD) from a hold rating to a sell rating in a report published on Monday morning, ValuEngine reports.

Other research analysts also recently issued reports about the company. Raymond James set a $60.00 price objective on Banner and gave the company a buy rating in a research note on Friday, May 3rd. Maxim Group reissued a buy rating and issued a $84.00 price objective on shares of Gilead Sciences in a research note on Friday, March 29th. Goldman Sachs Group set a $27.00 price objective on Melco Resorts & Entertainment and gave the company a buy rating in a research note on Tuesday, May 28th. UBS Group boosted their price objective on L Brands from $26.00 to $28.00 and gave the company a neutral rating in a research note on Wednesday, April 10th. Finally, Cowen set a $150.00 price objective on Tesla and gave the company a sell rating in a research note on Friday, May 3rd. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and fifteen have assigned a buy rating to the company. The stock presently has a consensus rating of Buy and a consensus price target of $79.54.

Shares of NASDAQ:GILD opened at $66.19 on Monday. The firm has a market cap of $85.93 billion, a P/E ratio of 10.76, a price-to-earnings-growth ratio of 3.19 and a beta of 1.12. The company has a debt-to-equity ratio of 1.09, a current ratio of 3.62 and a quick ratio of 3.53. The company has a 50-day simple moving average of $66.68. Gilead Sciences has a 1 year low of $60.32 and a 1 year high of $79.61.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported $1.76 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.53 by $0.23. The company had revenue of $5.28 billion for the quarter, compared to the consensus estimate of $5.29 billion. Gilead Sciences had a return on equity of 37.98% and a net margin of 26.40%. The firm’s revenue was up 3.8% compared to the same quarter last year. During the same period in the previous year, the business earned $1.48 EPS. Research analysts predict that Gilead Sciences will post 6.6 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which was paid on Thursday, June 27th. Investors of record on Friday, June 14th were paid a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 3.81%. The ex-dividend date was Thursday, June 13th. Gilead Sciences’s dividend payout ratio (DPR) is currently 40.98%.

In related news, Director John Francis Cogan sold 2,700 shares of the company’s stock in a transaction that occurred on Wednesday, April 24th. The stock was sold at an average price of $62.61, for a total transaction of $169,047.00. Following the transaction, the director now directly owns 57,560 shares of the company’s stock, valued at approximately $3,603,831.60. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, EVP Brett A. Pletcher sold 5,816 shares of the stock in a transaction that occurred on Tuesday, June 18th. The stock was sold at an average price of $68.75, for a total value of $399,850.00. Following the completion of the sale, the executive vice president now directly owns 27,198 shares of the company’s stock, valued at $1,869,862.50. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 14,084 shares of company stock worth $928,423. 0.20% of the stock is owned by company insiders.

Institutional investors have recently modified their holdings of the company. Capital Financial Planning LLC purchased a new stake in shares of Gilead Sciences in the fourth quarter worth approximately $27,000. Creative Financial Designs Inc. ADV raised its stake in shares of Gilead Sciences by 55.9% in the first quarter. Creative Financial Designs Inc. ADV now owns 460 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 165 shares during the last quarter. Claybrook Capital LLC purchased a new stake in shares of Gilead Sciences in the fourth quarter worth approximately $32,000. Weaver Consulting Group purchased a new stake in shares of Gilead Sciences in the first quarter worth approximately $34,000. Finally, Trustcore Financial Services LLC purchased a new stake in shares of Gilead Sciences in the first quarter worth approximately $34,000. 78.68% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Featured Article: What are the Benefits of Index Funds?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.